The ability of the microtubule destabilizers and, in some cell lines, ixabepilone, but not paclitaxel, to inhibit TGF-β-induced SNAI1 and Snail expression could be important for their clinical efficacy, especially in breast cancer patients whose tumours have undergone EMT. Here, TGFB1 is linked to breast carcinoma.